购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

OSI-930

Rating icon 很棒
产品编号 T2624Cas号 728033-96-3
别名 噻尔非尼, OSI 930

OSI-930 是 Kit,KDR 和 CSF-1R (c-Fms)的口服选择性抑制剂,IC50分别为 80 nM,9 nM 和 15 nM。它具有抗肿瘤活性,靶向肿瘤中的癌细胞增殖和血管生成。它还适度抑制 Flt-1,c-Raf 和 Lck,并且对 PDGFRα/β,Flt-3和 Abl 具有较弱的抑制活性。

OSI-930
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

OSI-930

Rating icon 很棒
纯度: 99.76%
产品编号 T2624 别名 噻尔非尼, OSI 930Cas号 728033-96-3

OSI-930 是 Kit,KDR 和 CSF-1R (c-Fms)的口服选择性抑制剂,IC50分别为 80 nM,9 nM 和 15 nM。它具有抗肿瘤活性,靶向肿瘤中的癌细胞增殖和血管生成。它还适度抑制 Flt-1,c-Raf 和 Lck,并且对 PDGFRα/β,Flt-3和 Abl 具有较弱的抑制活性。

规格价格库存数量
1 mg¥ 328现货
2 mg¥ 455现货
5 mg¥ 689现货
10 mg¥ 1,120现货
25 mg¥ 2,080现货
50 mg¥ 3,380现货
100 mg¥ 4,820现货
1 mL x 10 mM (in DMSO)¥ 773现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"OSI-930"的相关化合物库

选择批次:
纯度:99.76%
联系我们获取更多批次信息
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors.
靶点活性
CSF1R:15 nM, FLK1:8 nM, KDR:9 nM, C-Raf:41 nM, Lck:22 nM
体外活性
在HMC-1, NCI-SNU-5, COLO-205和U251移植瘤模型中,口服OSI-930(200 mg/kg)能够够抑制肿瘤细胞增殖.
体内活性
在HMC-1 细胞系中(IC50=14 nM),OSI-930抑制细胞增殖,诱导细胞凋亡。OSI-930能够抑制多种重组受体酪氨酸激酶,Kit(IC50=80 nM), KDR(IC50=9 nM), Flt( IC50=8 nM), CSF-1R(IC50=15 nM), c-Raf (IC50=41 nM)和Lck(IC50=22 nM)。
激酶实验
Protein kinase assays : Protein kinase assays are either done in-house by ELISA-based assay methods (Kit, KDR, PDGFRα, and PDGFRβ) or by a radiometric method. In-house ELISA assays used poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates; phosphorylation is then detected using an antiphosphotyrosine antibody conjugated to HRP. The bound antibody is then quantitated using ABTS as the peroxidase substrate by measuring the absorbance at 405/490 nm. All assays uses purified recombinant kinase catalytic domains that are either expressed in insect cells or in bacteria. The Kit and EGFR protein used for in-house assays are prepared internally; other enzymes are obtained. Recombinant Kit protein is expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and is initially purified as a nonphosphorylated (nonactivated) enzyme with a relatively high Km for ATP (400 μM). In some assays, an activated (tyrosine phosphorylated) form of the enzyme is prepared by incubation with 1 mM ATP for 1 hour at 30 °C. The phosphorylated protein is then passed through a desalting column to remove the majority of the ATP and stored at ?80 °C in buffer containing 50% glycerol. The resultant preparation has a considerably higher specific activity and a lower Km for ATP (25 μM) than the initial nonphosphorylated preparation. The inhibition of Kit autophosphorylation by OSI-930 is assayed by incubation of the nonphosphorylated enzyme at 30 °C in the presence of 200 μM ATP and various concentrations of OSI-930. The reaction is stopped by removal of aliquots into SDS-PAGE sample buffer followed by heating to 100 °C for 5 minutes. The degree of phosphorylation of Kit is then determined by immunoblotting for both total Kit and phosphorylated Kit.
细胞实验
For assays of cell proliferation and apoptosis, cells are seeded into 96-well plates and incubated for 2 to 3 days in the presence of OSI-930 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of the intracellular ATP content using CellTiterGlo. Induction of caspase-dependent apoptosis by OSI-930 is quantitated by an enzymatic caspase 3/7 assay. Inhibition of angiogenesis by OSI-930 is monitored using the rat aortic ring endothelial sprout outgrowth assay. Sections of aorta are prepared from CO2-euthanized male rats and cultured in vitro in a collagen matrix in the presence or absence of OSI-930. The collagen matrix is prepared from type 1 rat tail collagen solubilized in 0.1% acetic acid at 3 mg/mL, which is combined with 0.125 volume collagen buffer (0.05 N NaOH, 200 mM HEPES, 260 mM NaHCO3), 0.125 volume of medium 199, 0.0125 volume of 1 M NaOH, and 1% GlutaMax. Aortic rings are embedded in 0.4 mL of this matrix in six-well plates, to which 0.5 mL endothelial basal medium and the appropriate amount of OSI-930 is added; the rings are then incubated for 10 days and the resultant angiogenic sprout outgrowth is digitally quantitated from images by measurement of the sprout-containing area within a series of concentric rings around the aortic tissue area.(Only for Reference)
别名噻尔非尼, OSI 930
化学信息
分子量443.44
分子式C22H16F3N3O2S
CAS No.728033-96-3
SmilesFC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc2ccnc3ccccc23)cc1
密度1.450 g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 82 mg/mL (184.9 mM)
Ethanol: 3 mg/mL (6.76 mM)
溶液配制表
Ethanol/DMSO
1mg5mg10mg50mg
1 mM2.2551 mL11.2755 mL22.5510 mL112.7548 mL
5 mM0.4510 mL2.2551 mL4.5102 mL22.5510 mL
DMSO
1mg5mg10mg50mg
10 mM0.2255 mL1.1275 mL2.2551 mL11.2755 mL
20 mM0.1128 mL0.5638 mL1.1275 mL5.6377 mL
50 mM0.0451 mL0.2255 mL0.4510 mL2.2551 mL
100 mM0.0226 mL0.1128 mL0.2255 mL1.1275 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy OSI-930 | purchase OSI-930 | OSI-930 cost | order OSI-930 | OSI-930 chemical structure | OSI-930 in vivo | OSI-930 in vitro | OSI-930 formula | OSI-930 molecular weight